Evidence map›Paper›PMID 38658463›Full record

ArticleArchives of virology2024

Prevalence of the protective OAS1 rs10774671-G allele against severe COVID-19 in Moroccans: implications for a North African Neanderthal connection.

Fatima Zahra El Yousfi, Abbas Ermilo Haroun, Chaimae Nebhani, Jihane Belayachi, Omar Askander, Elmostafa El Fahime, Hakima Fares, Khalid Ennibi, Redouane Abouqal, Rachid Razine and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Advances in laboratory medicine · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Fatima Zahra El YousfiLaboratory of Human Genetics, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
Abbas Ermilo HarounLaboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
Chaimae NebhaniLaboratory of Human Genetics, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
Jihane BelayachiLaboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
Omar AskanderFaculty of Medical Science, Mohammed VI Polytechnic University, Benguerir, Morocco.
Elmostafa El FahimeMolecular Biology and Functional Genomics Platform, National Center for Scientific and Technical Research, Rabat, Morocco.
Hakima FaresIntensive Care Department, Cheikh Zaid International Universitary Hospital, Rabat, Morocco.
Khalid EnnibiVirology, Infectious and Tropical Diseases Center, Hopital Militaire d'Instruction Mohammed V, Rabat, Morocco.
Redouane AbouqalLaboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
Rachid RazineLaboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
Ahmed BouhoucheLaboratory of Human Genetics, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco. a.bouhouche@um5r.ac.ma.ORCID http://orcid.org/0000-0001-5279-8649
Mohammed V University · MAHôpital Universitaire International Cheikh Khalifa · MAUniversité Mohammed VI Polytechnique · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical presentation of COVID-19 shows high variability among individuals, which is partly due to genetic factors. The OAS1/2/3 cluster has been found to be strongly associated with COVID-19 severity. We examined this locus in the Moroccan population for the occurrence of the critical variant rs10774671 and its respective haplotype blocks. The frequency of single-nucleotide polymorphisms (SNPs) in the cluster of OAS immunity genes in 157 unrelated individuals of Moroccan origin was determined using an in-house exome database. OAS1 exon 6 of 71 SARS-CoV-2-positive individuals with asymptomatic/mild disease and 74 with moderate/severe disease was sequenced by the Sanger method. The genotypic, allelic, and haplotype frequencies of three SNPs were compared between these two groups. Finally, males in our COVID-19 series were genotyped for the Berber-specific marker E-M81. The prevalence of the OAS1 rs10774671-G allele in present-day Moroccans was found to be 40.4%, which is similar to that found in Europeans. However, it was found equally in both the Neanderthal GGG haplotype and the African GAC haplotype, with a frequency of 20% each. These two haplotypes, and hence the rs10774671-G allele, were significantly associated with protection against severe COVID-19 (p = 0.034, p = 0.041, and p = 0.008, respectively). Surprisingly, in men with the Berber-specific uniparental markers, the African haplotype was absent, while the prevalence of the Neanderthal haplotype was similar to that in Europeans. The protective rs10774671-G allele of OAS1 was found only in the Neanderthal haplotype in Berbers, the indigenous people of North Africa, suggesting that this region may have served as a stepping-stone for the passage of hominids to other continents.

Indexed as

2',5'-Oligoadenylate SynthetaseCOVID-19Polymorphism, Single NucleotideAdultAfrica, NorthernAgedAllelesFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeHaplotypesHumansMaleMiddle AgedNorth African People2',5'-Oligoadenylate SynthetaseOAS1 protein, human

Identifiers

PMID38658463
PMCPMC11043147
OpenAlexW4395462663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.